Literature DB >> 27391978

Ibrutinib is an effective treatment for B-cell prolymphocytic leukaemia.

Max J Gordon1, Philipp W Raess2, Kathleen Young1, Stephen E F Spurgeon1, Alexey V Danilov1.   

Abstract

Entities:  

Keywords:  cytogenetics; ibrutinib; prolymphocytic leukaemia

Mesh：

Substances：

Year:  2016        PMID： 27391978     DOI： 10.1111/bjh.14224

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  4 in total

1.  Sequential Kinase Inhibition (Idelalisib/Ibrutinib) Induces Clinical Remission in B-Cell Prolymphocytic Leukemia Harboring a 17p Deletion.

Authors:  H Coelho; M Badior; T Melo
Journal:  Case Rep Hematol       Date:  2017-07-27

Review 2.  How to Diagnose and Treat CD5-Positive Lymphomas Involving the Spleen.

Authors:  José Cabeçadas; Victor E Nava; Joao L Ascensao; Maria Gomes da Silva
Journal:  Curr Oncol       Date:  2021-11-11       Impact factor: 3.677

3.  Sustained MRD negative remission in del17p and TP53 mutated B cell prolymphocytic leukemia with ibrutinib and venetoclax.

Authors:  Maria Tariq Siddiqui; Allyson Price; Alessandra Ferrajoli; Gautam Borthakur
Journal:  Leuk Res Rep       Date:  2021-08-30

Review 4.  Zanubrutinib, rituximab and lenalidomide induces deep and durable remission in TP53-mutated B-cell prolymphocytic leukemia: a case report and literature review.

Authors:  Lijie Xing; Qiang He; Linna Xie; Hui Wang; Zengjun Li
Journal:  Haematologica       Date:  2022-05-01       Impact factor: 9.941
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.